Related Experiment Video
Updated: Jun 16, 2026

Models and Methods to Evaluate Transport of Drug Delivery Systems Across Cellular Barriers
Published on: October 17, 2013
An approach for the evaluation of closed system drug-transfer devices for transfer accuracy, particle release, and
Christian Lehermayr1, Sy Gebrekidan2, Serene Jabary3
1Novartis Pharma, Biologics Drug Product Development, Biochemiestraße 10, Langkampfen, Austria.
Abstract:
A Closed System Drug-Transfer Device (CSTD) is designed to prevent hazardous drugs from escaping their containers, thereby effectively safeguarding healthcare professionals from potential exposure. However, variations among CSTD designs may affect dose accuracy and overall quality of the drug product. This article proposes a standardized approach for evaluating CSTDs irrespective of product type. It addresses three critical attributes: transfer volume accuracy through residual hold-up volume measurements, device-related particle generation after exposure to drug surrogate solution, and standardized provision of comprehensive material-of-construction (MoC) data for all drug-contact components. The approach includes volume transfer across multiple vial sizes using a surfactant-containing surrogate solution at different viscosities to quantify dosing accuracy and residual loss after simulated use. The process also incorporates standardized particle analysis including USP 〈788〉 to detect subvisible particles shed by the device(s) after simulated use. A comprehensive and uniform MoC overview is also recommended to evaluate compatibility and monitor material modifications. The adoption of such a standardized approach by CSTD manufacturers would provide pharmaceutical companies with critical data to inform overfill requirements and compatibility assessments. Furthermore, it may potentially decrease the necessity for drug product-specific studies. Similarly, it may allow healthcare practitioners to enhance their compounding and administration practices by integrating CSTD performance data into their decision-making processes. In summary, adopting this harmonized evaluation framework for CSTDs would streamline device evaluation and integration in clinical practice, while safeguarding drug product quality and patient safety.
More Related Videos
06:08Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
Published on: March 11, 2017
08:47Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
Published on: September 28, 2022
Related Concept Videos
Drug Dissolution: Requirements and Profile Comparison
In Vitro Drug Dissolution: Compendial Testing Models II
In Vitro Drug Dissolution: Compendial Testing Models I
Modified-Release Drug Delivery Systems: Classification
In Vitro Drug Release Testing: Overview, Development and Validation
Transdermal Drug Delivery Systems